BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-42@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: AstraZeneca — Dato-DXd [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Investigate the Efficacy
  and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum
  Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer.\nSource: https://clinicaltr
 ials.gov/study/NCT06417814\nhttps://catalystbrief.girapphe.com/e/42?lang=e
 n\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/42?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
